Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. - Wikidata - wikimedia - TriplyDB

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

http://www.wikidata.org/entity/Q38884560

about

Biological agents in gastrointestinal cancers: adverse effects and their management.CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.Lokalisiertes prätibiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumab-Therapie wegen eines metastasierten Melanoms.Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.Willingness to pay for a cure of low-risk melanoma patients in Germany.Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor.Bilateral anterior uveitis after immunotherapy for malignant melanoma

P2860

Q33895581-9077E73C-7934-43C6-ADF5-6B545DD8AF04 Q37706688-8E032660-08FD-4967-A627-6C40C6431905 Q38672084-B06F4C63-A0B5-48DE-AE1D-53A2D370920E Q39308337-CBC8B736-F9CF-454E-9D90-B5E29078608B Q49497014-7A33AD2A-7E10-42B7-A422-A3426120C0F9 Q50123188-6C2C87CB-A998-4DF3-9870-E2256A322117 Q52722792-61598DC2-3C84-4B27-B953-7CD31D47A88B Q55137813-3314F1DC-BA8A-44E7-A554-D4D8B93C4988 Q55421581-D8647C3B-BAD6-48B1-8722-933E9B2B640A Q57193038-74B43394-6CA8-4C06-A52B-36E8D79ECF4F

P2860

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

http://www.wikidata.org/entity/Q38884560

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Management of side effects of ...... bodies in metastatic melanoma.

@en

type

label

Management of side effects of ...... bodies in metastatic melanoma.

@en

prefLabel

Management of side effects of ...... bodies in metastatic melanoma.

@en

P1433

Q38884560-B054B3B2-0E66-45EF-8954-0770CA95341E

P1476

Q38884560-700B9C0D-FEA0-498D-8C98-4EEFEB191A84

P2093

Q38884560-10B69715-59FD-4D01-9F4A-7367D152AE0B

Q38884560-3B0C40C1-5E42-4641-A50D-AF94CCA5FD5E

Q38884560-A57EEF9B-FC4F-4866-86E3-737B4ACC5664

Q38884560-B172FE2F-8B33-45C9-960D-9713F80B7DCF

Q38884560-DF20B5E6-4869-48E4-B86D-1DA72DDD2CF1

Q38884560-EE37CA1E-75AC-4B15-915C-B0D95FB1F0F5

Q38884560-F14CDB63-F04D-44DC-BB20-6391E28165F6

Q38884560-F46916D8-50C6-420C-B3E0-CBE7E856DAA0

P2860

Q38884560-0B5F8962-2508-41AC-BABD-97F5FEB89A10

Q38884560-0FCF6AB3-5B16-4D6E-8B85-9A19FC21710A

Q38884560-1051AC88-CD0C-4D26-915C-2F339BBDABD8

Q38884560-1BA9D858-72EA-43BC-9862-90E1BDFE32B2

Q38884560-1F161662-4B0D-44C0-A99A-A63D67DB9EFC

Q38884560-208D6974-41DD-4F72-9284-10DB836A3F56

Q38884560-23CB0434-B08B-47CC-94DE-DB841033A8F2

Q38884560-28CB756F-262F-4E1A-8646-676078C230CB

Q38884560-28F58AC9-3C06-4DBF-B2E5-0C1352D89BF0

Q38884560-2B219FFA-BB59-4FA4-8CE0-8B0D8CECA14B

P304

Q38884560-D8E09540-A993-4C41-9688-85F049E17CA1

P31

Q38884560-4F8C4938-54B2-45DE-B905-795D80AB8FF0

P356

Q38884560-ABA1875E-49FE-432D-8064-495C35543C5F

P433

Q38884560-E477D7E4-0A2B-4608-B5B9-1B4B6D667470

P478

Q38884560-D0EAEFC2-5B79-46B4-8F61-51D5CE36D1A0

P50

Q38884560-79AD35B8-9E21-4AFC-942C-7E3FEFFF9EB9

P577

Q38884560-8B9A2DDC-3119-45AD-9622-6A5716179992

P698

Q38884560-3E8697AB-39E8-48FA-AA59-EDFF80936662

P356

P1433

P1476

Management of side effects of ...... bodies in metastatic melanoma.

@en

P2093

Carmen Loquai

http://www.w3.org/2001/XMLSchema#string

Jessica C Hassel

http://www.w3.org/2001/XMLSchema#string

Katharina C Kähler

http://www.w3.org/2001/XMLSchema#string

Lisa Zimmer

http://www.w3.org/2001/XMLSchema#string

Lucie Heinzerling

http://www.w3.org/2001/XMLSchema#string

Ralf Gutzmer

http://www.w3.org/2001/XMLSchema#string

Rotraut Mössner

http://www.w3.org/2001/XMLSchema#string

“Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO)

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Toxicities of Immunotherapy for the Practitioner

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

P304

662-681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DDG.13047

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27373241

http://www.w3.org/2001/XMLSchema#string